Angion doses first patient in Phase II heart attack trial
The double-blind, placebo-controlled study is designed to evaluate the safety of BB3 for the treatment of heart attack (acute myocardial infarction) in conjunction with standard-of-care and its efficacy
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.